Studies Conducted at Tokyo University of Science on Dyslipidemias Recently Published (Association between statins and incidence of cancer in patients with dyslipidemia using large-scale health insurance claims data): Nutritional and Metabolic Diseases and Conditions – Dyslipidemias

2022 AUG 12 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on dyslipidemias is the subject of a new report. According to news reporting originating from Chiba, Japan, by NewsRx correspondents, research stated, “Recent experimental studies have examined the efficacy of statins in preventing cancer, but the findings of clinical studies are inconsistent, and studies on Japanese patients are limited.”

Our news correspondents obtained a quote from the research from Tokyo University of Science: “This study aimed to clarify the association between statins and cancer risk among Japanese patients. We conducted a large population-based retrospective cohort study using the Japanese health insurance claims database, including patients newly diagnosed with dyslipidemia between 2006 and 2015. Patients who were on newly prescribed statins during the study period were designated as statin users. They were matched 1:1 with randomly selected drug non-users who were not prescribed drugs for dyslipidemia according to age, sex, and year of first diagnosis of dyslipidemia. There were 23,746 patients in each group. The mean duration of follow-up for statin users and drug non-users was approximately 2 years.”

According to the news reporters, the research concluded: “Using a Cox proportional hazards model, significant reduction in cancer risk was observed in statin users compared with that in drug non-users (adjusted HR = 0.84, 95% CI = 0.72-0.97; adjusted for patient background factors). The results of subgroup analyses suggested that prescribed statins reduced the incidence of cancer of the digestive organs (adjusted HR = 0.79, 95% CI = 0.63-0.99) as well as reduced cancer risk in patients with non-smokers. Our results suggest that statin use may reduce cancer risk in patients with dyslipidemia.”

For more information on this research see: Association between statins and incidence of cancer in patients with dyslipidemia using large-scale health insurance claims data. Cancer Prevention Research, 2022. The publisher for Cancer Prevention Research is American Association for Cancer Research (AACR).

A free version of this journal article is available at https://doi.org/10.1158/1940-6207.capr-22-0087.

Our news editors report that more information may be obtained by contacting Ayako Maeda-Minami, Tokyo University of Science, Noda, Chiba, Japan. Additional authors for this research include Masayuki Takagi, Yasunari Mano, Hideki Ishikawa, Yutaka Matsuyama, Michihiro Mutoh.

ORCID is an identifier for authors and includes bibliographic information. The following is ORCID information for the authors of this research: Ayako Maeda-Minami (http://orcid.org/0000-0003-1361-4514), Masayuki Takagi (http://orcid.org/0000-0001-5646-1322), Yasunari Mano (http://orcid.org/0000-0002-2245-4260), Hideki Ishikawa (http://orcid.org/0000-0001-5980-698X), Yutaka Matsuyama (http://orcid.org/0000-0003-2009-6831), Michihiro Mutoh (http://orcid.org/0000-0003-2054-7655).

(Our reports deliver fact-based news of research and discoveries from around the world.)